Houston palliative care startup partners with new platform to expand reach

palliative care partnership

Health systems working with Dallas-based Guidehealth can now deploy Koda Health’s Advance Care Planning platform to help navigate end-of-life decisions. Photo via Getty Images.

Houston-based Koda Health and Dallas’ Guidehealth, an AI-powered health care services platform, announced a strategic partnership to provide access to tech-enabled solutions to help improve care and reduce costs for patients navigating serious illness.

Health systems and clinically integrated networks working with Guidehealth can now deploy Koda Health’s Advance Care Planning (ACP) platform, which allows patients to document and share their care preferences, goals and advance directives for health systems. Guidehealth’s platform integrates into primary care workflows and allows providers to identify high-risk patients, coordinate care and reduce administrative burden.

Guidehealth also works with a team of virtual caregivers, known as Guidehealth Healthguides, who help patients navigate end-of-life decisions. With this new partnership, the Healthguides will be able to integrate Koda Health’s ACP platform into their workflows.

“Koda Health’s mission is to ensure that every patient’s voice is heard, especially during the most vulnerable times in their lives,” Dr. Desh Mohan, Chief Medical Officer and co-founder of Koda Health, said in a news release. “This partnership with Guidehealth accelerates our ability to reach patients at scale, especially those in value-based arrangements where care alignment and quality of life are top priorities.”

Guidehealth works with more than 500,000 patients and major systems, such as Emory Healthcare, according to the release. The company closed a $14 million seed round last year, which included investment from Memorial Hermann.

“Advance care planning is essential to delivering care that is not just high quality, but also compassionate and aligned with what matters most to each patient,” Dr. Sanjay Doddamani, founder and CEO of Guidehealth, said in a news release. “Koda Health brings a scalable, digital-first approach to a historically complex and emotional process. By embedding Koda into our value-based care ecosystem, we’re equipping providers to have meaningful conversations with patients, reduce unnecessary interventions and ultimately improve the experience for families and clinicians alike.”

Koda Health was born out of the TMC's Biodesign Fellowship and was launched by CEO Tatiana Fofanova, Dr. Desh Mohan, and Katelin Cherry in March 2020. It closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. The company also added Kidney Action Planningto its suite of services in 2024.

From Your Site Articles
MD Anderson Cancer Center is still the best cancer-focused hospital in the U.S. and Texas. Photo by F. Carter Smith/courtesy of MD Anderson

Houston hospitals recognized as best in state, nation in annual report

better than all the rest

Houston’s University of Texas MD Anderson Cancer Center has retained its U.S. News & World Report crown as the best cancer hospital in the U.S.

In the same ranking, Houston Methodist Hospital once again came out on top as the best hospital in Texas. Last year, the hospital shared the top spot. Baylor St. Luke’s Medical Center ranked No. 4, followed by No. 5 Memorial Hermann Hospital.

The accolades appear in U.S. News’ 2024-25 ranking of the country’s best hospitals. Each hospital also ranked among various specialties, such as orthopedics; cardiology, heart, and vascular surgery; cancer; and neurology and neurosurgery.

Since U.S. News introduced its annual hospital survey in 1990, MD Anderson has been ranked one of the two best U.S. hospitals for cancer care. It has maintained its No. 1 ranking for 10 consecutive years.

“At MD Anderson, our mission is clear: to end cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “This ranking reflects our relentless commitment to excellence in patient care, research, prevention, and education.”

MD Anderson also ranked highly in three specialties:

  • No. 2 for ear, nose, and throat.
  • No. 9 for urology.
  • No. 14 for gastroenterology and GI surgery.

“The consistent top national recognitions [that] MD Anderson receives for delivering compassionate, evidence-based care is a testament to our dedication to those we serve,” Pisters says.

Elsewhere at the Texas Medical Center, Houston Methodist Hospital was named the No. 1 hospital in Texas for the 13th year in a row. Also, it was lauded as one of the country’s 20 best hospitals for the eighth time.

Along with the general ranking, Houston Methodist Hospital scored high marks in 10 specialties. These include diabetes and endocrinology (No. 6), gastroenterology and GI surgery (No. 7), and pulmonology and lung surgery (No. 8).

Meanwhile, four Houston Methodist community hospitals ranked well in Texas:

  • Houston Methodist The Woodlands Hospital (No. 8).
  • Houston Methodist Sugar Land Hospital (No. 9).
  • Houston Methodist Baytown Hospital (tied at No. 18).
  • Houston Methodist Willowbrook Hospital (tied at No. 23).
Koda Health has raised funding to fuel growth of its digital advance care planning company. Image via kodahealthcare.com

Houston digital health platform raises additional seed funding from fresh investors

money moves

A Houston-born digital advance care planning company, has secured new funding from some big names.

Koda Health achieved a successful oversubscription of additional seed round funding thanks to the participation of AARP, Memorial Hermann Health System, and the Texas Medical Center Venture Fund. The total amount raised was undisclosed, and the round was led by Austin-based Ecliptic Capital.

The tech platform improves planning for serious illness treatment and end-of-life care using a cloud-based advance care planning, or ACP, platform that pairs with in-house support. Essentially, it allows patients to do their planning ahead and make sure that their wishes are actually put into action. According to Koda Health, this results in an average of $9,500 saved per-patient, as well as improved health outcomes.

"If we’re looking at speed of market adoption, it’s clear that Koda Health is at the forefront of a crucial transformation in Advance Care Planning," says Tatiana Fofanova, PhD, CEO of Koda Health, in a press release. “In just a few years, we’ve built out a product that now serves well over 700,000 patients nationwide for industry giants like Cigna, Privia and Houston Methodist.”

Dr. Desh Mohan, the chief medical officer for Koda Health says that it was important to the company to create strategic partnerships with its investors. In fact, Memorial Hermann isn’t just helping with funding. The hospital system is also collaborating with Koda on a new pilot project.

“Koda is uniquely positioned to serve payers, providers and patients,” adds William McKeon, president and CEO of Texas Medical Center. “We rarely see a company that provides value to all three stakeholders. Seeing Koda launch from our TMCi BioDesign program to the progress they've made with our member institutions and players in the value chain is incredible.”

Beyond the TMC, Koda’s collaboration with AARP goes through the latter’s AgeTech Collaborative. That ecosystem unites founders in the realm of longevity tech to make meaningful change in their field.

"AARP research shows that there is a willingness among older adults in the U.S. to prepare for the end of their lives," says Amelia Hay, VP of Startup Programming and Investments at AgeTech Collaborative. "This indicates a need for more programs and services geared towards ensuring adults take the necessary steps, and AARP is pleased to invest in Koda Health to help address that need."

Koda raised its first seed funding in 2022, a round that totaled $3.5 million. The new round close means that Koda can accelerate its efforts to modernize ACP.

These Houston hospitals are the best in Texas and beyond. Photo via tmc.edu

Houston hospitals soar on annual list ranking best in Texas

top health care

Houston Methodist Hospital now shares its status as the state’s best hospital with Dallas’ UT Southwestern Medical Center.

In U.S. News & World Report’s latest ranking of Texas hospitals, Houston Methodist and UT Southwestern share the No. 1 spot. Last year, Houston Methodist was the lone holder of first-place honors in Texas.

The Houston Methodist system comprises a primary care facility within the Texas Medical Center and six community hospitals across the region. In all, Houston Methodist operates more than 2,600 patient beds and employs more than 29,700 people.

Overall, Houston hospitals fared well in this year’s Texas rankings:

  • Houston Methodist, No. 1
  • Baylor St. Luke’s Medical Center, No. 3
  • Memorial Hermann Hospital-Texas Medical Center, No. 4
  • Memorial Hermann Greater Heights Hospital, No. 6
  • Houston Medical Sugar Land Hospital, No. 9
  • Memorial Hermann Memorial Medical Center, No. 10

Specialty institutions in Houston also garnered accolades.

For instance, the University of Texas MD Anderson Cancer Center ranked first in the country for cancer care. Since the inception of the U.S. News & World Report survey in 1990, MD Anderson has been among the country’s top two institutions for cancer care.

“At MD Anderson, we remain singularly focused on eliminating cancer,” Dr. Peter WT Pisters, president of MD Anderson, says in a news release. “We are pleased to see this commitment recognized, but there is work still to be done.”

For its part, Houston Methodist nabbed national rankings in 10 specialties, including No. 4 for diabetes and endocrinology and No. 5 for gastroenterology and GI surgery.

Elsewhere in the Houston area:

  • Texas Children’s Hospital nailed down the No. 1 ranking among children’s hospitals in the state.
  • TIRR Memorial Hermann was again ranked as the Best Rehabilitation Hospital in Texas.
  • The Texas Heart Institute at Baylor St. Luke’s Medical Center claimed the No. 2 ranking among cardiovascular, heart, and vascular surgery facilities in the state.
  • The Menninger Clinic again makes the top 10 psychiatric hospitals. It ranked No. 7 in that specialty.

“A recent survey of U.S. News users revealed more than four in five (84 percent) consider a hospital’s quality metrics to be important factors when deciding where to seek treatment for a serious medical issue,” Ben Harder, chief of health analysis and managing editor at U.S. News, says in a news release. “Consumers want useful resources to help them assess which hospital can best meet their specific care needs.”

Harder adds that his publication’s hospital rankings “offer patients and the physicians with whom they consult a data-driven source for comparing performance in outcomes, patient satisfaction, and other metrics that matter to them.”

Houston's health tech and startup ecosystem has some recent news to catch up on. Photo via Getty Images

Houston health tech startups announce exec, funding — plus more innovation news

SHORT STORIES

Houston startup founders have been moving and shaking in the local innovation ecosystem — from growing their executive boards to raising fresh grant funding.

In this roundup of Houston startup and innovation news, a startup opens a crowdfunding round, a Houston hospital system taps into new technology, and more.

Coya Therapeutics names new president and chief medical officer

Fred Grossman will assume his new role next week. Photo via LinkedIn

Coya Therapeutics Inc. (NASDAQ: COYA), a revolutionary biotech company based in Houston, named Dr. Fred Grossman as president and chief medical officer. The clinical-stage company, which has developed a biologics therapy that prevents further spreading of neurodegenerative diseases by making regulatory T cells functional again, announced the closing of its $15.25 million IPO in January.

According to the company, Dr. Grossman's position, which was held by Dr. Adrian Hepner, is effective July 17.

“We are grateful for Dr. Hepner’s leadership and excellence in positioning Coya and look forward to having him continue to collaborate with the company in moving our assets forward," Howard H. Berman, CEO of Coya, says in a news release. "We also welcome Dr. Grossman, who brings decades of clinical development experience and successful execution."

Dr. Grossman has held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, Sunovion, Glenmark Pharmaceuticals, and Mesoblast Inc. (NASDAQ: MESO), developing allogeneic cellular therapies for inflammatory diseases.

CellChorus receives another SBIR grant

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured additional funding. Photo via Getty Images

Fresh off a $2.3 million grant last month, Houston-based CellChorus, a single-cell analysis company, has another grant to celebrate.

The U.S. National Science Foundation has awarded CellChorus a Small Business Innovation Research (SBIR) grant to advance development of its Time-lapse Imaging Microscopy In Nanowell Grids, known as TIMING. The funding will be used to develop novel microscale arrays to support scaling dynamic single-cell analysis.

“This funding will further development of novel arrays to build on the success of our early access laboratory based in Houston,” says Mohsen Fathi, head of technology at CellChorus, in a press release. “This project will support scaling the only platform that can evaluate migration, contact dynamics, killing, survival, subcellular activity, and biomolecule secretion for the same individual cell over time and in high throughput to improve development and delivery of novel therapies.”

According to the release, the company is receiving more than $274,000 as a part of the grant, but CellChorus has the potential of receiving up to $2 million from the second phase.

“This award builds on our recent funding from the National Institute of General Medical Sciences to advance development of a dedicated instrument platform for TIMING,” says Daniel Meyer, CEO of CellChorus, in the release.

Memorial Hermann partners with TMC-backed virtual OB-GYN care

Two Houston-area hospitals now have access to this digital health startup's platform. Photo via Getty Images

The Memorial Hermann Health System has entered into a partnership with Washington, D.C.-based Babyscripts, a virtual care platform for managing obstetrics. The company is backed by the Texas Medical Center's venture fund and has existing ties to the city.

"Memorial Hermann strives to make Greater Houston a place where every woman's pregnancy, delivery and postpartum experience is successful and safe. This innovative partnership is a continuation of that commitment," says Dr. Victoria Regan, vice president of Women's and Children's Services at Memorial Hermann, in a news release.

Now, Memorial Hermann patients will be able to access Babyscripts myJourney, an app that delivers educational content, email campaigns, satisfaction surveys, appointment reminders, and more. The first two hospitals to receive access are Memorial Hermann Memorial City Medical Center and Memorial Hermann The Woodlands Medical Center, with plans to expand the program.

"The ability to access adequate prenatal and postpartum care is one of the largest predictors of maternal and infant health outcomes," says Anish Sebastian, CEO and co-founder of Babyscripts in the release. "With Babyscripts, Memorial Hermann is able to streamline the maternal health experience across their system, adding opportunities for access and providing consistent, high-quality pregnancy care to all patients, regardless of race, income, geography or risk."

Earn Your Freedom launches crowdfunding campaign with Houston nonprofit's support

Earn Your Freedom is looking for financial support from its community. Photo via houston.impacthub.net

Earn Your Freedom, a Houston startup that's gamifying personal finance education, has launched its first crowdfunding campaign in partnership with Impact Hub Houston.

The goal for EYF is to raise $100,000 to support its gaming programs with local schools. Impact Hub Houston is the fiscal sponsor for the raise, which is officially live and open for contributions.

The innovative and interactive web and mobile video game, which officially launched earlier this year to celebrate Financial Literacy Month, was designed to help kids build a strong foundation in money management, economics and investment in a fun and engaging way. It features challenges and real-world scenarios such as renting a first apartment, opening a first bank account, budgeting at the grocery store, buying stocks and index funds and renting or buying real estate.

“We envision a society where financial literacy is accessible to all, and where individuals are enabled with the tools to take control of their financial futures," says Keely McEnery, EYF co-founder and COO, in a press release. "We are bridging the gap between education and application, stepping in before the real-world consequences take place.”

Some 200,000 local clients still have coverage thanks to the agreement. RSM Design

Memorial Hermann and Blue Cross reach crucial agreement for Houstonians

hand shake

Nearly 200,000 Memorial Hermann Hospital patients can take a deep breath after the hospital system announced on Friday, March 11, that it has reached a deal with Blue Cross Blue Shield of Texas.

Memorial Hermann's contract with the state's largest insurer expired at the start of the month after a disagreement over contracting out the hospital's physician's network.

Both organizations announced they no longer had a contract, meaning patients would have to pay out-of-network costs.

After ongoing negotiations, a four-year deal was made, and Blue Cross Blue Shield patients at Memorial Hermann should not experience any further disruption in their care, effective immediately.

"Through determined efforts on both sides, Blue Cross and Blue Shield of Texas has reached an agreement with the Memorial Hermann Health System and its physicians," the insurance provider said in a statement. "The new four-year agreement allows BCBSTX members continued access to Memorial Hermann hospitals throughout the Houston region while expanding future access to Memorial Hermann providers for our Blue Advantage HMO members."

---

Continue reading this on our news partner, ABC13.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

How Houston's innovation sector fared in 2025 Texas legislative session

That's a Wrap

The Greater Houston Partnership is touting a number of victories during the recently concluded Texas legislative session that will or could benefit the Houston area. They range from billions of dollars for dementia research to millions of dollars for energy projects.

“These wins were only possible through deep collaboration, among our coalition partners, elected officials, business and community leaders, and the engaged members of the Partnership,” according to a partnership blog post. “Together, we’ve demonstrated how a united voice for Houston helps drive results that benefit all Texans.”

In terms of business innovation, legislators carved out $715 million for nuclear, semiconductor, and other economic development projects, and a potential $1 billion pool of tax incentives through 2029 to support research-and-development projects. The partnership said these investments “position Houston and Texas for long-term growth.”

Dementia institute

One of the biggest legislative wins cited by the Greater Houston Partnership was passage of legislation sponsored by Sen. Joan Huffman, a Houston Republican, to provide $3 billion in funding over 10 years for the Dementia Prevention and Research Institute of Texas. Voters will be asked in November to vote on a ballot initiative that would set aside $3 billion for the new institute.

The dementia institute would be structured much like the Cancer Prevention and Research Institute of Texas (CPRIT), a state agency that provides funding for cancer research in the Lone Star State. Since its founding in 2008, CPRIT has awarded nearly $3.9 billion in research grants.

“By establishing the Dementia Prevention and Research Institute of Texas, we are positioning our state to lead the charge against one of the most devastating health challenges of our time,” Huffman said. “With $3 billion in funding over the next decade, we will drive critical research, develop new strategies for prevention and treatment, and support our healthcare community. Now, it’s up to voters to ensure this initiative moves forward.”

More than 500,000 Texans suffer from some form of dementia, including Alzheimer’s disease, according to Lt. Gov. Dan Patrick.

“With a steadfast commitment, Texas has the potential to become a world leader in combating [dementia] through the search for effective treatments and, ultimately, a cure,” Patrick said.

Funding for education

In the K-12 sector, lawmakers earmarked an extra $195 million for Houston ISD, $126.7 million for Cypress-Fairbanks ISD, $103.1 million for Katy ISD, $80.6 million for Fort Bend ISD, and $61 million for Aldine ISD, the partnership said.

In higher education, legislators allocated:

     
  • $1.17 billion for the University of Houston College of Medicine, University of Texas Health Science Center at Houston, UT MD Anderson Cancer Center, and Baylor College of Medicine
  • $922 million for the University of Houston System
  • $167 million for Texas Southern University
  • $10 million for the Center for Biotechnology at San Jacinto College.

Infrastructure

In the infrastructure arena, state lawmakers:

     
  • Approved $265 million for Houston-area water and flood mitigation projects, including $100 million for the Lynchburg Pump Station
  • Created the Lake Houston Dredging and Maintenance District
  • Established a fund for the Gulf Coast Protection District to supply $550 million for projects to make the coastline and ship channel more resilient

"Nuclear power renaissance"

House Bill 14 (HB 14) aims to lead a “nuclear power renaissance in the United States,” according to Texas Gov. Greg Abbott’s office. HB 14 establishes the Texas Advanced Nuclear Energy Office, and allocates $350 million for nuclear development and deployment. Two nuclear power plants currently operate in Texas, generating 10 percent of the energy that feeds the Electric Reliability Council Texas (ERCOT) power grid.

“This initiative will also strengthen Texas’ nuclear manufacturing capacity, rebuild a domestic fuel cycle supply chain, and train the future nuclear workforce,” Abbott said in a news release earlier this year.

One of the beneficiaries of Texas’ nuclear push could be Washington, D.C.-based Last Energy, which plans to build 30 micro-nuclear reactors near Abilene to serve power-gobbling data centers across the state. Houston-based Pelican Energy Partners also might be able to take advantage of the legislation after raising a $450 million fund to invest in companies that supply nuclear energy services and equipment.

Reed Clay, president of the Texas Nuclear Alliance, called this legislation “the most important nuclear development program of any state.”

“It is a giant leap forward for Texas and the United States, whose nuclear program was all but dead for decades,” said Clay. “With the passage of HB 14 and associated legislation, Texas is now positioned to lead a nuclear renaissance that is rightly seen as imperative for the energy security and national security of the United States.”

---

A version of this article first appeared on EnergyCapitalHTX.com.

View All Listings